Condition: Advanced Solid Cancer · Non Small Cell Lung Cancer · Esophageal Cancer · Sponsor: Ascentage Pharma Group Inc.
APG-2449 is a novel, orally active, multi-targeted tyrosine kinase inhibitor, which inhibits FAK, ALK, and ROS1 with nanomolar potencies. In preclinical studies, APG-2449 demonstrated potent antiproliferative activity in various cancer cell lines as a single agent. In combination treatment, APG-2449 enhanced anti-proliferative activities of several chemotherapeutic and targeted agents. It is indicated that APG-2449 may have a broad therapeutic potential for the treatment of human cancer as a single agent and in combination with other classes of anticancer drugs. APG-2449 is intended for the treatment of patients with advanced solid tumors. Upon completion of the Phase 1 dose escalation study to establish the maximum tolerated dose (MTD), dose-limiting toxicities (DLTs), and/or recommended phase 2 dose (RP2D), several phase Ib/II studies will be implemented accordingly.
This description comes directly from the study's public registry record.
Yifan Zhai, M.D., Ph.D. · +86-20-28069260 · yzhai@ascentage.com
Always discuss trial participation with your own doctor first.
| Beijing Cancer Hospital | Beijing, Beijing Municipality, China | Recruiting |
| Fujian Medical University Union Hospital | Fuzhou, Fujian, China | Not Yet Recruiting |
| Fujian Cancer Hospital | Fuzhou, Fujian, China | Not Yet Recruiting |
| Sun-Yat Sen University Cancer Center | Guangzhou, Guangdong, China | Recruiting |
| The First affiliated hospital, Sun Yat-sen University | Guangzhou, Guangdong, China | Recruiting |
| Henan Provincial Oncology Hospital | Zhengzhou, Henan, China | Recruiting |
| Union Hospital medical college Huazhong University of Science and Technology | Wuhan, Hubei, China | Recruiting |
| Hunan Provincial Oncology Hospital | Changsha, Hunan, China | Recruiting |
| Zhejiang Provincial Oncology Hospital | Hangzhou, Zhejiang, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03917043